DPT Laboratories to Offer Expertise on Topical Semi-solid Formulations at AAPS Seminar

DPT logo

(San Antonio; Oct. 20, 2015)DPT Laboratories, a contract development and manufacturing organization (CDMO) specializing in semi-solids and liquids, will be participating in a seminar with BASF at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Orlando, Fla.           

The session, “The Role of Topical Semi-solid Microstructure in Formulation Performance and Efficacy,” will be from 1 to 4 p.m. Oct. 27 in OCCC Room #3. Representatives from DPT, BASF, the U.S. Food and Drug Administration (FDA) and other organizations will participate. The event will be comprised of three presentations:

  • “Effect of Processing and Scale-Up on Microstructure” by Michael Lowenborg, senior manager of formulation and process development at DPT
  • “Considerations Relating to Product Quality Characterization for Topical Semi-solid Dosage Forms” by Dr. Sam Raney, the FDA’s scientific lead for topical and transdermal drug products
  • “Effect of Excipient Selection on Semi-solid Product Microstructure and Performance Attributes” by Norman Richardson, BASF’s global technical marketing manager for skin delivery.

In addition, a panel discussion and Q&A will be moderated by Bozena Michniak-Kohn, Ph.D., director of the Center for Dermal Research and the Laboratory for Drug Delivery at the New Jersey Center for Biomaterials.

“In this session, we’ll look at the large effect the microstructure has on the function and efficacy of these formulations,” said Lowenborg. “Relying on my experience at DPT for more than a decade, I’ll talk specifically about the impacts processing and scale-up have on microstructures.”

For more information on DPT’s development and manufacturing capabilities or its Centers of Excellence, talk to the DPT experts at Booth 911 at AAPS or visit

About DPT
DPT is a contract development and manufacturing organization (CDMO) helping pharmaceutical companies achieve clinical and commercial success. With five cGMP-compliant facilities in San Antonio, Texas and Lakewood, New Jersey, DPT applies a Quality by Design (QbD) methodology to investigate your product, and discover and deliver the optimal solutions from development through commercialization. We bring vast experience in resolving development and manufacturing challenges in sterile (aseptic) and non-sterile semi-solids and liquids. From drug preformulation and formulation, to analytical method development and technology transfers, to production and distribution, DPT is your partner all the way through full-scale worldwide commercialization — visit